NASDAQ$NEO
NeoGenomics Inc. · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported revenue of $87 million in the second quarter amid COVID-19 pandemic.
NeoGenomics reported a challenging second quarter due to the global COVID-19 crisis, which reduced both revenue and earnings. However, the company made several strategic moves and investments, including fortifying the balance sheet, investing in Inivata, launching liquid biopsy tests, globalizing Pharma Services, and operationalizing a high-capacity COVID-19 testing laboratory.
- Consolidated revenue decreased 14% to $87 million.
- Clinical Services revenue decreased 17% to $74 million.
- Pharma Services revenue increased 3% to $13 million.
- Pharma Services backlog increased 63% to $173 million.
Headline financials
Revenue & EPS history
NeoGenomics · Revenue · Quarterly
$87M
Forward guidance
No forward guidance was provided in the press release.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+2.1%
Avg return
Earnings day
+3.4%
Avg return
5 days after
+2.7%
Avg return
30 days after
53%
34 / 64 earnings
Positive
+28.1%
Q3 2013
Best reaction
-34.0%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.8% | +9.6% | +18.4% | |
| Q4 2025 | +0.5% | -13.1% | -28.1% | |
| Q3 2025 | -2.5% | -3.8% | +19.4% | |
| Q1 2025 | -34.0% | -22.8% | -26.1% | |
| Q4 2024 | -13.9% | -23.0% | -31.1% | |
| Q3 2024 | +9.3% | +11.5% | +21.6% | |
| Q2 2024 | +16.1% | +15.4% | +9.7% | |
| Q1 2024 | -8.3% | +0.5% | -8.0% | |
| Q4 2023 | +14.8% | +16.9% | +7.5% | |
| Q3 2023 | +9.6% | +3.2% | +19.1% | |
| Q2 2023 | -6.2% | -11.0% | -11.3% | |
| Q1 2023 | +19.2% | +26.4% | +13.9% | |
| Q4 2022 | +18.2% | +26.2% | +26.4% | |
| Q3 2022 | +23.1% | +58.5% | +70.0% | |
| Q2 2022 | +16.1% | +23.4% | +3.6% | |
| Q1 2022 | -10.1% | -10.1% | -18.1% | |
| Q4 2021 | +11.2% | +14.4% | -6.0% | |
| Q3 2021 | -11.1% | -6.7% | -34.5% | |
| Q2 2021 | -4.6% | -12.7% | +7.7% | |
| Q1 2021 | -11.6% | -19.5% | -14.0% | |
| Q4 2020 | -4.0% | +0.3% | -12.5% | |
| Q3 2020 | -5.0% | -6.5% | +9.0% | |
| Q2 2020 | +1.9% | +3.8% | +2.4% | |
| Q1 2020 | +2.4% | -14.1% | -8.7% | |
| Q4 2019 | -5.5% | -0.2% | -14.3% | |
| Q3 2019 | +11.3% | +8.7% | +23.7% | |
| Q2 2019 | +0.3% | +4.6% | +2.0% | |
| Q1 2019 | +2.9% | +11.3% | +2.4% | |
| Q4 2018 | +4.6% | +7.6% | +12.5% | |
| Q3 2018 | +15.0% | +12.1% | +3.7% | |
| Q2 2018 | -1.6% | -1.5% | -1.9% | |
| Q1 2018 | +5.2% | +7.0% | +21.1% | |
| Q4 2017 | +12.1% | +15.8% | +9.9% | |
| Q3 2017 | +4.2% | +3.2% | +12.2% | |
| Q2 2017 | +2.5% | +2.5% | +3.5% | |
| Q1 2017 | -11.6% | -12.2% | -13.3% | |
| Q4 2016 | +1.6% | +3.4% | -3.2% | |
| Q3 2016 | +11.6% | +10.1% | +29.4% | |
| Q2 2016 | -1.5% | -5.7% | -14.4% | |
| Q1 2016 | +5.8% | — | — | |
| Q4 2015 | +7.7% | — | — | |
| Q3 2015 | +0.7% | — | — | |
| Q2 2015 | -4.6% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | +0.5% | — | — | |
| Q3 2014 | +6.0% | — | — | |
| Q2 2014 | +24.2% | — | — | |
| Q1 2014 | +8.9% | — | — | |
| Q4 2013 | -10.6% | — | — | |
| Q3 2013 | +28.1% | — | — | |
| Q2 2013 | -3.5% | — | — | |
| Q1 2013 | -1.1% | — | — | |
| Q4 2012 | -10.9% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | -3.5% | — | — | |
| Q1 2011 | -0.6% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.6% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | -3.4% | — | — | |
| Q4 2010 | -3.7% | — | — | |
| Q3 2010 | +9.1% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | -1.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro